| Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? DJ Mott The Patient-Patient-Centered Outcomes Research 11 (3), 249-252, 2018 | 46 | 2018 |
| Valuing EQ-5D-Y-3L health states using a discrete choice experiment: do adult and adolescent preferences differ? DJ Mott, KK Shah, JM Ramos-Goñi, NJ Devlin, O Rivero-Arias Medical Decision Making 41 (5), 584-596, 2021 | 32 | 2021 |
| Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy DJ Mott, M Najafzadeh Expert Review of Pharmacoeconomics & Outcomes Research 16 (1), 33-39, 2016 | 21 | 2016 |
| EQ-5D-Y Value Set for Germany S Kreimeier, D Mott, K Ludwig, W Greiner, IHTAH Group PharmacoEconomics, 2022 | 13 | 2022 |
| Challenges in valuing temporary health states for economic evaluation: a review of empirical applications of the chained time trade-off method J Stoniute, DJ Mott, J Shen Value in Health 21 (5), 605-611, 2018 | 11 | 2018 |
| Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR special interest group report C Vass, M Boeri, S Karim, D Marshall, B Craig, KA Ho, D Mott, ... Value in Health 25 (5), 685-694, 2022 | 9 | 2022 |
| Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences DJ Mott, N Chami, T Tervonen Value in Health 23 (8), 979-984, 2020 | 9 | 2020 |
| Conducting a time trade-off study alongside a clinical trial: a case study and recommendations J Shen, S Hill, D Mott, M Breckons, L Vale, R Pickard PharmacoEconomics-Open 3, 5-20, 2019 | 8 | 2019 |
| A multinational European study of patient preferences for novel diagnostics to manage antimicrobial resistance DJ Mott, G Hampson, MJ Llewelyn, J Mestre-Ferrandiz, MM Hopkins Applied Health Economics and Health Policy 18, 69-79, 2020 | 5 | 2020 |
| Public preferences for health gains and cures: a discrete choice experiment G Hampson, D Mott, N Devlin, K Shah Office of Health Economics, London, 2019 | 4 | 2019 |
| PCN382-quality of life in long-term cancer survivors: Implications for future health technology assessments in oncology P Cubi-Molla, DJ Mott, K Shah, M Herdman, Y Summers, C Tsuchiya, ... Value in Health 21, S79, 2018 | 4 | 2018 |
| A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE H Payne, A Robinson, B Rappe, S Hilman, U De Giorgi, S Joniau, ... International Journal of Cancer, 2021 | 3 | 2021 |
| Does changing the age of a child to be considered in EQ-5D-Y-3L DCE based valuation studies affect health preferences? O Rivero Arias, JM Ramos-Goñi, A Estévez Carrillo, D Rowen, D Mott, ... Value in Health 25 (7), 2022 | 2 | 2022 |
| Analytical considerations when anchoring discrete choice experiment values using composite time trade-off data: the case of EQ-5D-Y-3L DJ Mott, NJ Devlin, S Kreimeier, R Norman, KK Shah, O Rivero-Arias PharmacoEconomics, 1-9, 2022 | 1 | 2022 |
| Criteria for developing, assessing and selecting candidate EQ-5D bolt-ons BJ Mulhern, C Sampson, P Haywood, R Addo, K Page, D Mott, K Shah, ... Quality of Life Research 31 (10), 3041-3048, 2022 | 1 | 2022 |
| Considering Severity in Health Technology Assessment: Can We Do Better? C Skedgel, N Henderson, A Towse, D Mott, C Green Value in Health 25 (8), 1399-1403, 2022 | 1 | 2022 |
| Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments? P Cubi-Molla, D Mott, N Henderson, B Zamora, M Grobler, M Garau Office of Health Economics Research Papers, 2021 | 1 | 2021 |
| Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention DJ Mott, L Ternent, L Vale The European Journal of Health Economics, 1-11, 2022 | | 2022 |
| How is Quality of Life Measured for Health Technology Assessments? D Mott, G Kumar, C Sampson, M Garau Briefings, 2021 | | 2021 |
| Impact of Including Carer Information in Time Trade-Off Tasks: Results from a Pilot Study DJ Mott, I Leslie, KK Shah, J Rowell, N Scheuer PharmacoEconomics - Open, 2021 | | 2021 |
